Lifecore Biomedical, Inc. De (LFCR) Cash from Financing Activities (2010 - 2025)

Lifecore Biomedical's Cash from Financing Activities history runs 16 years deep, the most recent figure standing at -$402000.0 for Q2 2025.

• In Q2 2025, Cash from Financing Activities rose 34.53% year-over-year to -$402000.0; the TTM figure through May 2025 stood at $6.4 million (down 14.46% YoY), while the FY2025 annual figure was $6.4 million, down 14.45% from the prior year.
• Cash from Financing Activities was -$402000.0 for Q2 2025 at Lifecore Biomedical, up from -$6.8 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $24.6 million in Q2 2023 to a low of -$47.1 million in Q1 2022.
• Historically, Cash from Financing Activities has averaged $843777.8 across 5 years, with a median of $3.4 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities tumbled 506.36% in 2022, then soared 611.23% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at $9.9 million in 2021, then decreased by 10.82% to $8.8 million in 2022, then slumped by 127.79% to -$2.4 million in 2023, then jumped by 611.23% to $12.5 million in 2024, then tumbled by 103.21% to -$402000.0 in 2025.
• The last three Cash from Financing Activities figures came in at -$402000.0 (Q2 2025), -$6.8 million (Q1 2025), and $12.5 million (Q4 2024), per Business Quant data.